Mikhail Blagosklonny is an American based research scientist who has devoted his life’s work to studying the effects of cancer and methods of mitigating the disease. He is an expert in Oncology and lectures at Roswell Park Cancer Institute. Mikhail graduated with his Masters and Doctor of Philosophy degree from the First Pavlov State Medical University of St. Petersburg. In the year 2002, he was appointed as an associate professor of medicine at New York Medical College. Later, he took a position with Ordway Research Institute as a senior scientist. Blagosklonny worked in this post until an opportunity at Roswell Park Cancer Institute presented itself. View Mikhail’s profile on Google Scholar.
The Blagosklonny research aims at developing therapies that target the cancer cells without causing damage to the healthy cells. In the aspect of aging, Mikhail is involved in the development of drugs that helps suppress aging. His extensive research on age-related diseases has led to the development of rapamycin that is used today to slow down the aging process. He has published over 300 articles, reviews, and book chapters. Mikhail is also involved in several editorial tasks. He is the chief editor of Cell Cycle, a journal that details the path undertaken by the cell during its development. He is also the co- editor and founder of Aging, Oncotarget, and Oncoscience. These three journals are responsible for publishing scientific findings and making breakthroughs available to the public in the shortest time. Additionally, he has served as an associate editor for Cancer Biology and Therapy. Blagosklonny has acted as an editor for Autopathy, Cancer Research, Cell Death and Differentiation, The American Journal of Pathology, and PLOS ONE.
With the aim of inhibiting cancer and the aging process, Mikhail Blagosklonny sought to identify the role of TOR signaling in the development of cancer tumors and aging. According to the scientist, rapamycin, a popular drug administered to cancer patients can be used to treat and extend life. When administered in monitored doses, the drug can prevent cell failure and retinopathy without any side effects. He is a passionate advocate of rapamycin. At Roswell Park Cancer Institute, Mikhail has been able to facilitate the development of new anti-cancer methods through several prevention and therapy techniques. Visit ResearchGate.Net to learn more about Mikhail’s latest work.